Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 8Neoplasm Metastasis 5Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Stomach Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Liver Neoplasms 1Leukemia 1Kidney Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Advanced Tumor 1Advanced Solid Malignancies 1Advanced Prostate Adenocarcinoma 1Advanced Breast Cancer 1

Interventions

Fulvestrant 13Letrozole 6Anastrozole 5palbociclib 4exemestane 3Injections 3Docetaxel 3Paclitaxel 2Goserelin 2Dasatinib 2Capecitabine 2Alpelisib 2AZD9833 2vandetanib 1ribociclib 1irinotecan sucrosofate 1entinostat 1elacestrant 1cediranib 1abemaciclib 1XMT-1522 1Vinorelbine 1Sirolimus 1Ritonavir 1Lead 1Itraconazole 1Immunotherapy, Adoptive 1Everolimus 1Decitabine 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Breast Cancer × cediranib × Clear all
NCT00454805 2016-08-03

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

AstraZeneca

Phase 2 Completed
75 enrolled 11 charts
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡